Neuroendocrine Carcinoma Clinical Trials in Houston, Texas

6 recruitingHouston, Texas

Showing 16 of 6 trials

Recruiting
Phase 2Phase 3

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine CarcinomaMetastatic Extrapulmonary Neuroendocrine CarcinomaRecurrent Extrapulmonary Neuroendocrine Carcinoma+1 more
National Cancer Institute (NCI)189 enrolled244 locationsNCT05058651
Recruiting
Phase 2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Stage IV Prostate Cancer AJCC v8Metastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation+1 more
National Cancer Institute (NCI)30 enrolled13 locationsNCT05691465
Recruiting

Establishing a Tumor Registry for Patients With Neuroendocrine Carcinoma of the Cervix

Stage III Cervical Cancer AJCC v8Stage IIIA Cervical Cancer AJCC v8Stage IIIB Cervical Cancer AJCC v8+19 more
M.D. Anderson Cancer Center750 enrolled1 locationNCT04723095
Recruiting
Phase 1

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Small Cell Lung Cancer Metastatic or Locally AdvancedNeuroendocrine CancerMetastatic or Locally Advanced Neuroendocrine Prostate Cancer+5 more
SystImmune Inc.120 enrolled20 locationsNCT07080242
Recruiting
Not Applicable

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

Stage I Colorectal Cancer AJCC v6 and v7Stage II Colorectal Cancer AJCC v7Stage III Colorectal Cancer AJCC v7+45 more
M.D. Anderson Cancer Center590 enrolled1 locationNCT01365169
Recruiting
Phase 1Phase 2

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Breast CancerEsophageal CancerGastric Cancer+13 more
Tanabe Pharma America, Inc.27 enrolled6 locationsNCT06943521